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Repeated nicotine administration has been associated with increased paradoxical sleep in rats and 
antinociceptive properties, whereas paradoxical sleep deprivation (PSD) elicits pronociceptive and 
inflammatory responses. Thus, we aimed to evaluate the effect of repeated nicotine administration 
and its withdrawal combined with PSD on pain sensitivity and inflammatory markers. Sixty adult 
male Wistar rats were subjected to repeated injections of saline (SAL) or nicotine (NIC) for 12 days 
or 7 days of nicotine followed by acute mecamylamine administration on day 8 to precipitate 
nicotine abstinence (ABST). On day 9, the animals were submitted to PSD for 72 h or remained in 
control condition (CTRL); on day 12, thermal pain threshold was assessed by the hot plate test. PSD 
significantly decreased the latency to paw withdrawal in all groups compared to their respective 
controls. ABST-PSD animals presented higher levels of interleukin (IL)-6 compared to all groups, except 
ABST-CTRL. After adjustment for weight loss, IL-6, IL-4 and tumor necrosis factor alpha, ABST-PSD 
was associated with the lowest pain threshold. Nicotine and IL-4 levels were predictors of higher pain 
threshold. Hyperalgesia induced by PSD prevailed over the antinociceptive action of nicotine, while the 
association between PSD and ABST synergistically increased IL-6 concentrations and decreased pain 
threshold.
As a stimulant of the central nervous system, nicotine may affect sleep pattern in both humans and rodents1,2. 
In nonsmokers, acute nicotine administration has been associated with a dose-dependent reduction of rapid eye 
movement (REM) sleep and slow-wave sleep3,4. When in nicotine abstinence, a significant increase in total sleep 
time and REM sleep rebound occur3. In rats, acute nicotine administration has also been reported to decrease 
both paradoxical sleep and slow-wave sleep in a dose-dependent manner2. Nevertheless, during repeated admin-
istration, nicotine leads to an increase of paradoxical sleep2, possibly mediated by neuronal nicotinic acetylcho-
line receptors (nAChR) in the pontine reticular formation of rats5,6. Moreover, after mecamylamine-induced 
withdrawal, nicotine-treated animals display a normal sleep pattern2.
Animal models of chronic pain present decreased percentage of time in paradoxical sleep, suggesting an 
important role of REM sleep in pain regulation7,8. Conversely, paradoxical sleep deprivation (PSD) may elicit 
higher pain sensitivity in rodents9,10. On the other hand, both systemic and intrathecal administrations of nicotine 
have demonstrated antinociceptive properties in different animal models of pain6,11,12 as well as anti-inflammatory 
properties13–15.
Considering that nicotine and PSD exert opposed effects on nociception, this work aimed to evaluate the 
effects of repeated nicotine administration and its withdrawal combined with PSD on pain sensitivity. We hypoth-
esized that chronic nicotine treatment would at least partially counteract the effects of PSD on pain sensitivity in 
association with higher anti-inflammatory and lower pro-inflammatory cytokines levels. In addition, we expected 
that during nicotine withdrawal, PSD would lead to the highest levels of pain sensitivity and pro-inflammatory 
cytokines. Secondarily, we aimed to investigate the independent predictors of pain threshold.
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Results
Body Weight Loss due to Sleep deprivation. Animals were either treated with saline (SAL), nicotine 
for 12 days (NIC) or nicotine for seven days followed by an injection of mecamylamine to precipitate nicotine 
withdrawal and five more days of saline treatment (ABST). On day 9, the animals were distributed into two 
conditions: normal sleep (CTRL) or 72 h of PSD, thus resulting in six experimental groups. The experimen-
tal protocol is represented in Fig. 1. The delta body weight (the difference between body weight at day 12 and 
day 1) for each group is shown in Fig. 2. PSD groups had a significant body weight loss in comparison to the 
CTRL groups (F1,54 = 236.4, p < 0.0001), independent of nicotine treatment. Additionally, a treatment effect was 
observed (F2,54 = 22.5, p < 0.0001), revealing that NIC animals had lower body weight gain compared to both SAL 
(p < 0.0001) and ABST groups (p < 0.0001). Additionally, a post-hoc test of the univariate analysis showed that 
among CTRL groups, delta body weight was lower only in NIC-CTRL compared to both SAL-CTRL (p = 0.001) 
and ABST-CTRL (p < 0.0001) groups. Similarly, NIC-PSD group presented lower delta body weight compared to 
both SAL-PSD (p < 0.0001) and ABST-PSD (p = 0.003) groups.
Figure 1. Experimental protocol. Experimental timeline for each condition: SAL-CTRL (saline treatment 
followed by control sleep condition, n = 10), NIC-CTRL (nicotine sensitization followed by control sleep 
condition, n = 10), ABST-CTRL (nicotine sensitization and mecamylamine-induced withdrawal followed by 
control sleep condition, n = 10), SAL-PSD (saline treatment followed by 72 h of paradoxical sleep deprivation 
(PSD), n = 10), NIC-PSD (nicotine sensitization followed by 72 h of PSD, n = 10), ABST-PSD (nicotine 
sensitization and mecamylamine-induced withdrawal followed by 72 h of PSD, n = 10).
Figure 2. Body weight. Difference between final (Day 12) and initial (Day 1) body weight in animals submitted 
to a 12-day saline (SAL) treatment, a 12-day nicotine (NIC, 3.2 mg/kg/day) treatment or a 7-day NIC treatment 
followed by mecamylamine-induced withdrawal (1.5 mg/kg) and subsequently exposed to control sleep 
condition (CTRL) or 72 h paradoxical sleep deprivation (PSD) (n = 10 per group). *p < 0.0001 compared to 
the respective SAL group (CTRL or PSD); #p < 0.0001 compared to the respective ABST group (CTRL or PSD); 
**p < 0.0001 significant effect of PSD.
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Sleep Deprivation Overcame the Analgesic Effect of Nicotine. Nociceptive sensitivity was assessed 
by the hot plate test, in which the animal is placed over a heated plate and the latency to paw withdrawal is used as 
a measure of pain threshold and sensitivity. This result is shown in Fig. 3. When not adjusted for any confounder, 
the analysis of the latency to paw withdrawal demonstrated treatment (F2,54 = 9.4, p < 0.0001), PSD (F1,54 = 93.2, 
p < 0.0001) and interaction effects (F2,54 = 5.2, p < 0.01). Overall, NIC animals showed a higher latency to 
paw withdrawal when compared to both SAL (p < 0.0001) and ABST groups (p < 0.0001). Alternatively, PSD 
led to a shorter latency in all the three groups (SAL-PSD, NIC-PSD and ABST-PSD) compared to SAL-CTRL 
(p < 0.0001), NIC-CTRL (p < 0.0001) and ABST-CTRL (p < 0.0001), respectively. However, a post-hoc test of 
the interaction effect revealed that only the NIC-CTRL group had a significant increase in pain threshold com-
pared to SAL-CTRL (p < 0.0001), SAL-PSD (p < 0.0001), NIC-PSD (p < 0.0001), ABST-CTRL (p = 0.005), and 
ABST-PSD (p < 0.0001) groups. No significant changes in pain sensitivity were observed among the PSD groups 
(SAL-PSD, NIC-PSD, and ABST-PSD).
After adjusting for potential confounders or mediators (delta body weight; tumor necrosis factor alpha, 
TNF-α; interleukin 4, IL-4; and IL-6), we also observed treatment (F2,54 = 24.2, p < 0.0001), PSD (F1,54 = 33.0, 
p < 0.0001) and interaction effects (F2,54 = 13.7, p = 0.001). However, post-hoc tests of interaction effect showed 
that PSD significantly decreased pain threshold only in NIC-PSD (18.1 ± 7.7 s) and ABST-PSD (11.0 ± 3.8 s) 
groups compared to NIC-CTRL (49.8 ± 10.9 s, p < 0.0001) and ABST-CTRL (30.1 ± 10.4 s, p < 0.0001), respec-
tively. No significant changes were observed between SAL-PSD (16.3 ± 4.9 s) and SAL-CTRL (26.1 ± 9.4, 
p = 0.142). As in the unadjusted analysis, NIC-CTRL presented higher pain threshold compared to all other 
groups (p < 0.0001). Additionally, ABST-PSD exhibited the lowest pain threshold, which statistically differed 
from SAL-CTRL (p < 0.0001), NIC-CTRL (p < 0.0001), ABST-CTRL (p < 0.0001) and NIC-PSD (p = 0.040) 
groups, with a trend of difference compared to SAL-PSD (p = 0.082).
Sleep Deprivation and Nicotine Abstinence Increased IL-6 concentrations. No significant effects 
were observed in the plasmatic concentrations of the anti-inflammatory cytokines IL-4 and IL-10. (Fig. 4A,B). 
However, there was a significant interaction effect on plasmatic TNF-α concentrations (F2,54 = 5.1, p < 0.01); 
and treatment (F2,54 = 6.3, p < 0.01) and interaction (F2,54 = 6.1, p < 0.05) effects on IL-6 concentrations. Post-hoc 
tests showed that the ABST-PSD group presented higher concentrations of TNF-α compared to SAL-PSD 
(p = 0.001), which in turn showed lower concentrations compared to the SAL-CTRL (p = 0.001) group (Fig. 4C). 
Overall, higher levels of IL-6 were found in the ABST animals compared to both SAL (p = 0.001) and NIC groups 
(p < 0.0001). Post-hoc analysis of the interaction effect revealed, however, that this increase in IL-6 levels occurred 
specifically in the ABST-PSD group compared to SAL- SAL-PSD (p = 0.020) and NIC-PSD (p = 0.006) as well 
as compared with CTRL (p = 0.026) and NIC-CTRL (p = 0.006) groups (Fig. 4D). No other differences were 
observed between groups.
Nicotine Treatment, Sleep Deprivation, and IL-4 as Predictors of Pain Sensitivity. A correlation 
matrix between the latency to paw withdrawal, the delta body weight and the immunological parameters was 
calculated for the whole sample to reveal possible factors associated with pain threshold (Table 1).
Then, a generalized linear model was fitted considering the latency to paw withdrawal as the dependent varia-
ble (Table 2). The best model included PSD (Wald: 15.7, df: 1, p < 0.0001), treatment (Wald: 24.5, df: 1, p < 0.0001) 
and IL-4 (Wald: 5.9, df: 1, p < 0.05) as the independent predictors of the latency to paw withdrawal (Likelihood 
ratio χ2 = 96.3, df: 9, p < 0.0001, n = 60). An increase in 10 pg/mL of plasmatic IL-4 corresponded to an average 
increase of 6% in the latency to paw withdrawal, thus revealing an association between higher plasmatic con-
centrations of IL-4 and a higher pain threshold. Additionally, PSD was associated with an average decrease of 
49.9% in the latency to paw withdrawal compared to CTRL condition, while repeated nicotine administration 
was associated with an average increase of 63.8% in comparison with saline administration, as shown in Table 2.
Within SAL-CTRL and NIC-CTRL groups, it was observed a moderate positive correlation between 
paw withdrawal latency and IL-4 levels (Supplementary Table 1). A trend (p = 0.07) was also found in the 
Figure 3. Pain sensitivity. Mean ± standard deviation of latency to paw withdrawal (s) in the hot plate test in 
animals submitted to a 12-day saline (SAL) treatment, a 12-day nicotine (NIC, 3.2 mg/kg/day) treatment or a 
7-day NIC treatment followed by mecamylamine-induced withdrawal (1.5 mg/kg) and subsequently exposed 
to control sleep condition (CTRL) or 72 h paradoxical sleep deprivation (PSD) (n = 10 per group). *p < 0.001 
compared to SAL-CTRL; #p < 0.0001 compared to ABST-CTRL; **p < 0.05 significant effect of PSD.
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ABST-CTRL group, which showed a positive correlation of IL-6 and IL-10 levels with paw withdrawal latency 
(Supplementary Table 1). Body weight loss was only correlated with paw withdrawal latency in the SAL-PSD 
group (Supplementary Table 1).
Figure 4. Plasmatic cytokines. Mean ± standard deviation of anti-inflammatory cytokines interleukin (IL)-4 
(pg/mL, A) and IL-10 (pg/mL, B) and, pro-inflammatory cytokines tumor necrosis factor (TNF)-α (pg/mL, 
C) and IL-6 (pg/mL, D) in plasma samples from animals submitted to a 12-day saline (SAL) treatment, a 12-
day nicotine (NIC, 3.2 mg/kg/day) treatment or a 7-day NIC treatment followed by mecamylamine-induced 
withdrawal (1.5 mg/kg) and subsequently exposed to control sleep condition (CTRL) or 72 h paradoxical sleep 
deprivation (PSD) (n = 10 per group). *p < 0.05 compared to SAL-PSD; #p < 0.05 compared to NIC-PSD.
R p
Δ Body weigth 0.58 <0.0001
IL-4 0.26 <0.05
IL-6 −0.01 >0.05
IL-10 −0.07 >0.05
TNF-α 0.14 >0.05
Table 1. Correlation of latency to paw withdrawal with weight loss and plasmatic concentrations of cytokines 
(n = 60). Δ: Delta (difference between final and initial); IL: interleukin; TNF-α: tumor necrosis factor alfa; R: 
Pearson correlation coefficient; p: statistical significance.
OR 95% CI χ2 p
(Constant) — 14.091–27.228 313.384 <0.0001
Sleep
   PSD 0.501 0.356–0.705 15.674 <0.0001
   CTRL Reference
Treatment
   Nicotine 1.638 1.311–2.046 18.922 <0.0001
   Mecamylamine* 0.953 0.796–1.142 0.272 >0.05
   Saline Reference
   IL-4 1.006 1.001–1.010 5.848 <0.05
Table 2. Statistically significant predictors of paw withdrawal latency resulting from the generalized linear 
model (tweedie regression, n = 60). CI: confidence interval; IL-4: interleukin 4; OR: odds ratio; PSD: paradoxical 
sleep deprivation; χ2: Wald chi-square value; *refers to the protocol of nicotine withdrawal.
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Discussion
Our results have shown that both nicotine and PSD independently affected thermal pain sensitivity, leading either 
to a decrease or to an increase in paw withdrawal latency, respectively. When associated, the pronociceptive effects 
of PSD prevailed over the antinociceptive effects of nicotine treatment, with PSD animals displaying hyperalgesia 
regardless of previous repeated nicotine administration. PSD combined with nicotine abstinence synergistically 
increased the plasmatic concentrations of IL-6. Additionally, when body weight loss, TNF-α, IL-4 and IL-6 levels 
were included in the model as confounders, ABST-PSD animals showed the lowest pain threshold compared to 
all groups, with no significant difference compared to the SAL-PSD group. The regression model demonstrated 
that repeated nicotine administration and higher concentrations of IL-4 were independent predictors of higher 
thermal pain threshold, while PSD was associated with a 50% decrease in pain threshold in the hot plate test.
As part of the mesolimbic dopaminergic pathway, nucleus accumbens seems to mediate the reinforcing and 
aversive effects of nicotine and its withdrawal16,17, as well as to play a role in pain modulation18,19. Nicotine has 
been shown to increase synaptic dopamine and D2 receptor sensitivity in the nucleus accumbens20–22. Both D1 
and D2 dopamine receptors are expressed by neurons in the ventrolateral periaqueductal gray (vlPAG), playing a 
central role in morphine and dopamine-induced antinociception23,24. The vlPAG act as an output system respon-
sible for integrating afferent inputs from multiple forebrain areas to modulate nociception at the spinal dorsal 
horn25. Recently, Umana et al. has shown that 63% of the projections from vlPAG to the rostral ventromedial 
medulla express α7 nicotinic acetylcholine receptors (nAChR), suggesting a model of α7 nAChR-mediated anal-
gesia in the vlPAG26. In their study, systemic and intra-vlPAG administration of an α7 nAChR-selective agonist 
showed an antinociceptive effect in the formalin assay, which was blocked by intra-vlPAG α7 antagonist pretreat-
ment27. Nicotine administration increased GABAergic transmission via presynaptic nAChRs of both α7-lacking 
and α7-expressing neurons in the vlPAG of rats27. Previous evidence indicates that nicotine might exert its 
antinociceptive effect mainly through modulation of α4β2 nAChRs6,28,29. Activation of α4β2 nAChRs results in 
stimulation of dorsal raphe, nucleus raphe magnus, and locus coeruleus in a norepinephrine (NE)-dependent 
fashion27–30. These areas play a significant role in pain modulation through descending inhibitory pathways, 
underlying in part the nicotine-induced antinociception31. In addition, systemic administration of nicotine sig-
nificantly increases the release of endogenous opioids such as endorphins, enkephalins, and dynorphins in the 
supraspinal cord via α7 nAChR30.
Of note, vlPAG descending pathway seems to be the key site by which PSD increases nociceptive responses 
in rats. A recent study showed that PSD decreased morphine-induced analgesia by modulation of the vlPAG in 
rats31. Moreover, Sardi and colleagues27 have shown that the nucleus accumbens also mediates the pronocicep-
tive effect of PSD through activation of A2A adenosine receptors and inhibition of D2 dopamine receptors. In 
this study, an excitotoxic lesion of the nucleus accumbens prevented the PSD-induced hyperalgesia, which was 
reverted by an acute blockade of this region through either an A2A adenosine antagonist or a D2 dopamine ago-
nist27. Considering that A2A receptors are also largely involved in the homeostatic regulation of the sleep-wake 
cycle32, we might speculate that the role of nucleus accumbens A2A receptors in the pronociceptive effect of PSD 
would also be linked to sleep pressure. The greater the sleep need, the greater the A2A receptors activity, and, thus, 
the lower the pain threshold27.
Sleep deprivation has been shown to decrease D2 receptor expression in the nucleus accumbens of humans33 
but to increase its sensitivity in rats subjected to 96 h of PSD34, though it has been shown that freely moving 
rats exhibit higher concentrations of dopamine in the nucleus accumbens during REM sleep35. Considering that 
vlPAG receives projections from nucleus accumbens neurons expressing A2A receptors, a possible integrative 
mechanism for the pronociceptive effects of PSD could rely on the increased nucleus accumbens A2A activity, 
leading to an activation of the vlPAG descending pathway. Even though there is no study assessing a role of 
nucleus accumbens adenosine receptors in pain processing, the use of adenosine receptor agonists has shown 
potent antinociceptive effects in animal models of chronic pain36. Spinal cord neurons expressing A2A adenosine 
receptors seems to mediate antinociception, inhibiting symptoms of neuropathic pain37. On the other hand, the-
ophylline (an adenosine receptor antagonist) reduced antinociception induced by nicotine in the formalin test38. 
Taken together the evidence from the literature, we can speculate that in our study PSD overcame the antinocic-
eptive effects of nicotine pretreatment by inhibiting the pain inhibitory descending vlPAG pathway through A2A 
receptor activation and D2 receptor inhibition in the nucleus accumbens27. Possibly, the antinociceptive effects 
of nicotine involved multiple pathways, including activation of α4β2 nAChRs29 and of spinal A2A receptors36, 
release of opioids at the spinal cord30 as well as nucleus accumbens activation with projections to vlPAG through 
α7 nAChR26.
Pro-inflammatory cytokines, such as IL-6 and TNF-α, exert known pro-nociceptive effects through central 
and peripheral action and are implied in the pathophysiology of neuropathic pain39–42. We observed an increase 
in plasmatic concentrations of IL-6 when nicotine abstinence and PSD were associated. Nonetheless, there was 
no correlation between pain threshold and the cytokines in the ABST-PSD group possibly due to the strong 
pro-nociceptive effect of PSD itself, leading to a ceiling effect. However, when we adjusted the analysis of pain 
threshold for delta body weight, IL-6, IL-4 and TNF-α, the ABST-PSD group showed the lowest latency to paw 
withdrawal, suggesting a synergic effect of nicotine withdrawal and PSD. Our findings point towards an inflam-
matory component in thermal sensitivity, as IL-4 was a predictor associated with pain threshold, although it 
did not differ statistically between the groups. With the observed OR of 1.006 and the mean concentration of 
IL-4 = 32.04 pg/mL, IL-4 may account on average for 21.13% of the thermal pain threshold variability in our 
sample. Thus, IL-4 may partially explain endogenous spontaneous individual differences in pain threshold, inde-
pendent of nicotine treatment or of PSD. Animal studies have shown that both IL-4 and IL-10 exert an antino-
ciceptive effect in various models of inflammatory pain; however, both cytokines were unable to increase pain 
threshold in control animals43–45. Although IL-4 up-regulates the expression of opioid receptors, the opioid antag-
onist naloxone did not reverse the antinociceptive effect of IL-4 in a model of inflammatory pain45. In addition, 
www.nature.com/scientificreports/
6SCieNtiFiC RePoRtS |  (2018) 8:13837  | DOI:10.1038/s41598-018-32276-7
IL-4 knockout mice did not demonstrate a lower latency in the hot plate test, yet showed a lower pain threshold in 
the von-Frey test46. This discrepancy of results might be explained by different species used and different physio-
logical conditions, as IL-4 seems to exert an antinociceptive effect more prominently in hyperalgesic conditions. 
From a translational point of view, a clinical study has found lower proteic and mRNA expression of IL-4 and 
IL-10 in patients with chronic pain47.
PSD is known to cause a low-grade inflammation in rats primarily through an elevation of the cytokines IL-1β, 
IL-6, and TNF-α compared to controls48–51. However, data from the literature is contradictory, possibly due to dif-
ferences in sleep deprivation models, protocol specificities, and different animal strains used. In our study, 72 h of 
PSD did not have an independent effect on TNF-α and IL-6 levels. On the contrary, the SAL-PSD group showed 
a decrease in the TNF-α levels compared to the SAL-CTRL group, contributing to the statistical difference found 
between ABST-PSD and SAL-PSD. We should consider that our study design involved chronic daily subcutane-
ous injections (twice a day), which is not the same as having naïve animals. All animals displayed similar high lev-
els of corticosterone at the end of the protocol (data not shown), indicating that the daily injections were possibly 
stressful to the animals and should be considered in the interpretation of the data. Taking into consideration the 
possible effect of stress in a context of a pro-inflammatory stimulus, we found evidence from the literature that 
may help explain the unexpected finding of TNF-α. Rats exposed to heat stress or to sodium arsenite 18 h prior to 
lipopolysaccharide (LPS) administration, a well-known pro-inflammatory stimulus, had significantly lower levels 
of plasma TNF-α – instead of higher – leading to a decreased mortality and lung injury52. This finding suggests a 
protective or preconditioning effect of stress response before a pro-inflammatory stimulus. Thus, we could spec-
ulate that the stress involved in the subcutaneous daily injections altered the expected pro-inflammatory effect of 
PSD in saline-treated animals as a preconditioning stimulus.
Nicotine, on the contrary, exerts an anti-inflammatory effect in animal models, decreasing the levels of 
pro-inflammatory cytokines, namely, IL-1β, IL-6, TNF-α, and IL-1713,14,53. In our study, the lack of statistical 
differences in plasma concentrations of pro-inflammatory and anti-inflammatory cytokines between NIC-CTRL 
and SAL-CTRL groups may be due to the lack of an injury stimulus, since the previous studies in which nicotine 
showed an anti-inflammatory action were performed in different contexts, such as LPS administration, virus 
infection, and lung injury13,14,53. The anti-inflammatory effects of nicotine seem to be modulated by the choliner-
gic anti-inflammatory pathway15, mainly through α7 nAChRs in immune cells. Prolonged exposure to nicotine 
inactivates both α7 and α4β2 nAChRs54–56. Thus, another possibility could be the development of tolerance to the 
anti-inflammatory effects of nicotine via α7 desensitization induced by the chronic nicotine treatment, contrib-
uting to the effect of nicotine abstinence.
Our study indicates that nicotine abstinence combined with PSD may synergistically increase IL-6 levels. 
Vagal tone is decreased in sleep-deprived rats57, which, in addition to desensitization of α7 receptors in response 
to repeated nicotine administration, might explain the synergistic interaction effect of nicotine withdrawal and 
PSD on plasmatic concentrations of IL-6. Our data suggest that, during nicotine abstinence, sleep deprivation 
may predispose the organism to inflammation.
It is important to consider the limitations of the current study. Although we followed a very consistent and 
standardized protocol of mecamylamine-induced abstinence, we did not assess the behavioral signs of nicotine 
withdrawal in the animals. We recognize that the use of additional tests based on mechanical or chemical pain 
sensitivity could avoid a ceiling effect of PSD in the pain threshold assessment, and possibly allow a further 
understanding of the interactions between PSD and nicotine administration/withdrawal. Also, the concentra-
tions were determined in animals that had undergone the hot plate test and an effect of test exposure on cytokine 
concentrations should not be ruled out. Additionally, central nervous systems cytokine concentrations could 
yield additional information about neural pathways underlying the interaction between PSD and nicotine and its 
effects on nociception. Lastly, we did not include a reinstatement group of nicotine after its withdrawal.
Conclusion
Our study confirmed the previously observed effects of nicotine and PSD on nociception and showed that the 
PSD-induced pronociceptive effects largely prevailed over nicotine-induced antinociception. When associated 
with PSD, however, nicotine abstinence synergistically increased IL-6 levels and independently decreased pain 
threshold. Higher levels of IL-4 were independently associated with higher pain threshold.
Methods
Animals. Sixty 12-week-old male Wistar rats were obtained from Centro de Desenvolvimento de Modelos 
Experimentais para Medicina e Biologia (CEDEME, Universidade Federal de São Paulo, São Paulo, Brazil). 
All experiments were approved by the Animal Ethics Committee of Universidade Federal de São Paulo 
(#742480/2013) and followed international ethical standards58, complying with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals (8th Edition, revised 2011) and the recommendations of the 
American Association for Accreditation of Laboratory Animal Care. Animals were maintained in groups of five 
per cage in individually ventilated cages (Tecniplast, Italy) in a temperature-controlled room (23 ± 1 °C) with a 
12:12 h light-dark cycle (lights off at 19 h). Food and water were provided ad libitum throughout the protocol.
Drugs and Treatment. Nicotine-treated animals received 3.2 mg/kg/day of nicotine (nicotine hydro-
gen tartrate, Sigma, USA) in 2 daily subcutaneous (s.c.) injections for 12 days. This dose has been known to 
reliably induce nicotine dependence59–61. In order to establish nicotine abstinence, rats were first sensitized 
to nicotine during 7 days, a period that has been shown to be sufficient to induce sensitization to nicotine in 
adult rats62,63. Animals in the abstinence group were then acutely treated with mecamylamine hydrochloride 
(2-methylaminoisocamphane hydrochloride, Sigma, USA) on day 8 at 7 h and 19 h (1.5 mg/kg, s.c.). For the 
remainder of the days (days 9 through 12) animals in the abstinence groups received solely saline injections 
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twice a day (s.c.). Mecamylamine is a non-competitive nicotinic cholinergic receptor antagonist that precipitates 
symptoms of nicotine abstinence in sensitized rats 1 day after its administration64. A previous study demon-
strated significant effects of mecamylamine dose on intracranial self-stimulation thresholds and total somatic 
signs (withdrawal-like signs), with significant increases in both measures at the 1.5 mg/kg dose64. The nicotine 
dose chosen for inducing abstinence symptoms upon mecamylamine treatment has been previously described 
elsewhere64,65.
All drugs were diluted in sterile physiologic saline (0.9%) and had their pH corrected for 7.4. Subcutaneous 
injections were always administered in 1.0 mL/kg volume. Animals from the sham groups were treated with saline 
similarly to the other groups.
Paradoxical Sleep Deprivation. Animals were submitted to 72 h of PSD using the modified multiple plat-
form method66. Groups of 5 animals were housed in a water-filled tank (143 × 41 × 30 cm) containing 12 circular 
platforms (6.5 cm in diameter), whose surface was 1 cm above the water level. Rats could move jumping from one 
platform to another. When animals reach paradoxical sleep phase, they experience loss of muscle tone and fall 
into the water, being awakened. Groups of 5 sleep control animals were housed in home cages out of ventilated 
racks in the same room as the PSD animals during this protocol. We elected to choose neither a too long (96 h) 
nor a too short period (24 h) of PSD. However, the literature is not consistent about the effects of 48 h of PSD on 
thermal pain sensitivity67. Asakura and colleagues did not find significant differences in the latency of paw with-
drawal in the hot plate test after 48 h of PSD. With regard to 72 h of PSD, however, most of the studies showed a 
significant hyperalgesic effect in thermal pain sensitivity9,68. Thus, we chose 72 h of PSD since it would certainly 
lead to hyperalgesia in the hot plate test and not be considered ethically aggressive as 96 h of PSD.
Nociceptive Evaluation. Thermal pain sensitivity was evaluated using the hot plate test69 in a protocol pre-
viously used in sleep-deprived animals9,70. During the test, each animal was individually placed in a 50 °C-heated 
hot plate apparatus, and the latency to paw withdrawal was measured as an estimation of pain threshold. At 
the first sign of paw withdrawal, i.e., a behavior of paw licking or jumping as an attempt to escape, the rat was 
removed from the hot plate. The test had a maximum duration of 90 s to avoid paw lesions and burns. The hot 
plate was cleaned with ethanol 30% between each test.
Sample Collection. At the end of the experimental protocol (Day 12), rats were rapidly decapitated with 
minimum discomfort after the hot plate test. The euthanasia schedule was standardized at 8 h. Blood was col-
lected into sterile tubes with liquid EDTA and centrifuged at 4 °C and 1300 g for 10 min to obtain separated 
plasma. Plasma samples were frozen at −20 °C for further analyses.
Cytokines Concentrations. For cytokine quantification, the Luminex® platform (Millipore, USA) was 
used following manufacturer’s instructions. Milliplex® Map kits (Rat Cytokine/Chemokine Panel) were used to 
determine the plasma concentration of interleukin (IL)-4, IL-6, IL-8, IL-10, and tumor necrosis factor (TNF)-α. 
Briefly, each cytokine binds to its specific antibody-coated microsphere, which contains 2 fluorochromes. This 
combination of fluorochromes allows for the determination of which cytokine is bound to each microsphere. 
Additionally, another antibody binds to the cytokine-microsphere complex, thus determining the concentration 
of each cytokine.
Statistical Analysis. All continuous data were firstly tested for normality and homogeneity. Variables with-
out normal distribution or homogeneity among the groups were standardized by z-score. Between-group com-
parisons were performed using 2-way analysis of variance (ANOVA) test considering treatment (SAL, NIC or 
ABST) and sleep condition (CTRL or PSD) as independent variables. For treatment effect or interaction effect, 
the statistical difference was calculated using Bonferroni post-hoc. Body weight at the beginning and the end of 
the protocol was compared by repeated measures 2-way ANOVA, followed by Bonferroni’s post-hoc if necessary. 
To further understand the independent effects of treatment, sleep condition and its interactions, multiple analysis 
of covariance (MANCOVA) was performed for latency to paw withdrawal (dependent variable) with adjustment 
for the potential covariates (delta body weight, TNF-α, IL-4 and IL-6). Pairwise comparisons were performed by 
Bonferroni’s post-hoc. Correlations between continuous data were calculated through Pearson’s correlation test. 
Finally, a generalized linear model with tweedie distribution and log link function was applied to establish pre-
dictor variables for pain sensitivity using latency to paw withdrawal as the dependent variable and body weight 
variation, treatment, sleep deprivation, and cytokines as the independent variables. For statistical significance, we 
adopted α = 0.05.
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